Editorial Outlines the Use of Biomarkers in Diagnosing Alzheimer’s, Parkinson’s, and Lou Gehrig’s Diseases
Power3 Medical Products, Inc’s (OTCBB: PWRM, http://www.power3medical.com) director of proteomics, Dr. Ira Goldknopf, has published an invited editorial in the February 2008 issue of Expert Review of Proteomics. Power3 Medical is a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases.
The editorial, entitled “Blood Based Proteomics for Personalized Medicine, Examples From Neurodegenerative Disease,” outlines how “proteins in the blood serum can tell us what disease pathways and mechanisms…are active in patients.” In his editorial, Dr. Goldknopf cited research completed at Power3 and published in peer reviewed journals. The results demonstrate, “broad and deep implications which liberate a new paradigm to unlock the power of personalized medicine, to monitor proteins in the blood of live patients for diagnosis, differential diagnosis, patient monitoring, selection of treatment options, and for new drug target discovery.”
Dr. Goldknopf continues in the piece: “It is critical to have the ability to diagnose these neurodegenerative diseases more accurately, earlier, and faster than currently available. In addition, the ability to monitor specific disease processes in the patients’ blood will ultimately lead to more effective and personalized treatments.”
“Power3 Medical is gratified that the editors of Expert Review of Proteomics invited Dr. Goldknopf to share his insights and to describe Power3’s groundbreaking work in the study of Alzheimer’s, Parkinson’s, and Lou Gehrig’s diseases,” said Steve Rash, CEO of Power3. “We are proud the biotechnology community has recognized and acknowledged Power3’s efforts and advancements in disease diagnosis through blood-based testing. This recognition of our company, represented by Dr. Goldknopf, is further validation of Power3’s leadership position in advancing the science of proteomics for development of molecular diagnostics and targeted therapeutics for neurodegenerative diseases and breast cancer.”
Power3 is currently pursuing ongoing commercialization efforts for its biomarkers and its blood serum test, BC-SeraPro™ for the early diagnosis of breast cancer, and NuroPro™, a blood serum test for the early diagnosis of neurodegenerative diseases. The company currently has several ongoing clinical validation trials at multiple national and international sites. The BC-SeraPro™ breast cancer test is commercially available in several Middle Eastern countries through a distribution agreement. The NuroPro™ test for neurodegenerative diseases will follow soon thereafter.
About Power3 Medical Products
Power3 Medical Products, Inc. (OTCBB: PWRM, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro™, in twelve Middle Eastern countries before the end of 2007. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas. The Company is preparing to commercialize its IP portfolio, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s, and Parkinson’s Diseases.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.
Power3 Medical Products, Inc.
Steven B. Rash, 281-466-1600
srash@power3medical.com
or
The
Investor Relations Group
Investor Relations:
Adam Holdsworth /
Rachel Colgate /
Erica Ruderman, 212-825-3210
or
Media
Relations:
Laura Colontrelle / Janet Vasquez, 212-825-3210